PDE6A

The PDE6A gene provides the recipe for the alpha subunit of an enzyme called phosphodiesterase 6, which works inside rod photoreceptors. Rods are the light-sensing cells that handle vision in dim light and around the edges of your visual field. This enzyme breaks down a chemical messenger called cGMP, which controls the electrical current flowing through the rod cell (definition: A type of photoreceptor used for vision in low light and peripheral (side) vision. RP usually affects rod cells first.). In this way PDE6A is a key part of phototransduction, the process that transmits and amplifies the visual signal. Because the condition is autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.), a person typically needs an altered copy of the gene from each parent to be affected.

Since rods depend on this enzyme, PDE6A-related disease usually behaves as a rod-cone dystrophy, affecting night and peripheral vision earlier than central, detailed vision. In a French cohort study, night blindness was the presenting symptom in most people with PDE6A variants, more often than in the related PDE6B form. A longitudinal study of 16 people with PDE6A-associated retinitis pigmentosa found that most had only mild loss of central visual acuity and slowly progressive changes on retinal imaging. That same study noted a hyperautofluorescent ring on imaging in about half of eyes, and cystoid macular edema (fluid-filled spaces in the central retina) in more than half of eyes. Presentation can vary from person to person; one reported woman noticed night blindness in her early twenties yet retained excellent central acuity. In a pediatric cohort, children found to have rod-cone dystrophy including PDE6A were sometimes without noticeable symptoms at the time of genetic diagnosis.

PDE6A is an established cause of autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.) retinitis pigmentosa, and its role in rod phototransduction is well characterized. In a large French cohort of people with rod-cone dystrophy, PDE6A variants accounted for a small share of cases, confirming it is a rare but recognized cause. In populations where marriage between relatives is common, such as Pakistan, PDE6A has been reported as a leading genetic cause of inherited retinal disease, so how often it appears varies across populations. Natural history evidence points toward generally slow progression and relatively preserved central vision for many people, though this is based on modest numbers followed at specialist centers.

The exact age of onset, rate of progression, and severity differ between individuals and cannot be predicted from the gene result alone. When more than one retinal gene is involved, or when a PDE6A change is a variant of uncertain significance found alongside another gene, the picture becomes harder to interpret and may need careful genetic analysis. Whether gene therapy (definition: A treatment that delivers a working copy of a gene into cells to take over for a copy that isn't functioning properly.) can meaningfully benefit people with PDE6A-related disease remains unproven; the first published early-phase human trial did not show improvement over one year.

As of this review, no therapy targeting PDE6A has been approved, and current care focuses on monitoring, supporting remaining vision, and managing complications such as macular fluid. A subretinal gene therapy (definition: A treatment that delivers a working copy of a gene into cells to take over for a copy that isn't functioning properly.) that delivers a working copy of PDE6A using an adeno-associated virus (AAV) vector has been tested in an early-phase human trial of nine people. In that trial the treatment did not improve visual function over one year and carried risks including thinning of the central retina and some loss of visual acuity, which the authors noted contrasted with earlier animal results. Safety studies in monkeys that preceded the trial found that a single subretinal injection was tolerated at lower doses, but that higher doses caused retinal atrophy, which helped set the starting dose. Other approaches remain experimental and have so far only been tested in laboratory and animal models, including precise gene-editing techniques that corrected the mutation and preserved photoreceptors in mice.

• Early-phase gene therapy trial for PDE6A

  Non-randomised clinical trial (human)

  What was found:

  No systemic adverse events occurred, but visual function did not improve and some persistent problems appeared, including central retinal thinning and moderate acuity loss.

  Why it matters:

  It is the first published human test of PDE6A gene supplementation and shows that benefit in people has not yet been demonstrated.

  Limitation: Very small, uncontrolled dose groups with only one year of follow-up.

• Safety testing of PDE6A gene therapy in monkeys

  Preclinical animal safety study

  What was found:

  Lower and intermediate doses were well tolerated, while the highest dose caused retinal atrophy and abnormal electrical responses, which set the trial's starting dose.

  Why it matters:

  It illustrates how animal safety data guided the human study and flagged retinal atrophy as a dose-related risk.

  Limitation: Findings in healthy animal eyes may not fully predict outcomes in affected human retinas.

• Gene-editing repair of PDE6A in mice

  Preclinical laboratory and animal research

  What was found:

  The prime editing approach corrected the mutation with modest efficiency, restored PDE6A protein, and preserved photoreceptors and retinal function in treated mice.

  Why it matters:

  It is a proof-of-concept that precise editing might one day address PDE6A mutations, though it is far from clinical use.

  Limitation: Only tested in mice with one mutation; not a treatment available to people.

• Long-term follow-up of PDE6A and PDE6B rod-cone dystrophy

  Observational human cohort study

  What was found:

  Night blindness was a more common first symptom in the PDE6A group, and the two genes accounted for small, similar shares of rod-cone dystrophy cases with comparable slow decline in acuity and visual field.

  Why it matters:

  It helps set expectations for the general course of PDE6A disease and supports planning for future therapies.

  Limitation: It was retrospective, from a single referral center, and included a modest number of PDE6A patients.

• Natural history of PDE6A-associated retinitis pigmentosa

  Observational, longitudinal human study

  What was found:

  Most had mild loss of central visual acuity and slowly progressive changes, with a hyperautofluorescent ring in about half of eyes and frequent cystoid macular edema.

  Why it matters:

  It provides measurable markers that could be used to judge disease progression and treatment effects.

  Limitation: Small number of patients and relatively short average follow-up.

Because PDE6A disease is autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.), siblings of an affected person have a chance of being affected or of being unaffected carriers, and both parents are typically carriers, which a genetic counselor can explain for your family. Children with rod-cone dystrophy from PDE6A may have few or no symptoms early on, so families may wish to discuss eye monitoring even before difficulties are obvious.

• Have both of my PDE6A variants been confirmed as disease-causing, or is either a variant of uncertain significance?
• Based on my current retinal imaging and testing, what pattern and rate of change have you seen so far?
• Do I have any signs of cystoid macular edema that might be treatable?
• Would a natural history study be appropriate for me, and what would participation involve?
• How might my results affect my children, siblings, or other relatives?
• What follow-up schedule and vision tests do you recommend to track any changes over time?

Confirming the specific PDE6A variants and how they were inherited, ideally with a genetic counselor, can help clarify the diagnosis and options. Because several observational and natural history studies are ongoing, a retinal specialist can discuss whether monitoring or research participation might be relevant. You can use RP Hope's Clinical Trials Finder to explore studies with PDE6A in mind, where any eligibility would be confirmed by the study team.